604 Results for "

SCO2 mutations

" in MedChemExpress (MCE) Product Catalog:
Products (604)

604 Results for "SCO2 mutations" in MCE Product Catalog:

Cat. No.: HY-P9S0124
Synonyms: ORM-6151 Antibody; BMS-986497 Antibody

Research Areas:  

Cancer

Anti-CD33 Antibody (OR000283) (ORM-6151 Antibody; BMS-986497 Antibody) is an antibody targeting CD33. It is generated by grafting the FAb (H&L) sequence of Gemtuzumab (HY-P99971) onto an IgG1 Fc carrying the N297A mutation, which inhibits Fc-γR binding. Anti-CD33 Antibody (OR000283) can be used to construct degrader-antibody conjugates (DACs), such as ORM-6151 (HY-171792) [2].
loading...
    loading...
Cat. No.: HY-104036R
CAS No.: 1628805-46-8
IDH-305 (Standard) is the analytical standard of IDH-305 (HY-104036). This product is intended for research and analytical applications. IDH-305 is an orally available, mutant-selective and brain-penetrant IDH1 inhibitor that targets IDH1 (R132) mutation. IDH-305 exhibits greater than 200 fold selectivity for mutant IDH1 isoforms vs. WT (IC50= 27 nM (IDH1R132H), 28 nM (IDH1R132C), 6.14 µM (IDH1WT)) [2].
loading...
    loading...
Cat. No.: HY-109061BR
CAS No.: 2247995-37-3
Synonyms: YH25448 mesylate (Standard); GNS-1480 mesylate (Standard)
Target:  

Reference Standards

Research Areas:  

Cancer

Lazertinib mesylate (Standard) is the analytical standard of Lazertinib (mesylate) (HY-109061B). This product is intended for research and analytical applications. Lazertinib (YH25448) mesylate is a potent, selective, CNS-penetrant, orally available and irreversible EGFR tyrosine Kinase inhibitor, exhibiting high selectivity for activating (EGFRm) and T790M resistance mutations. Lazertinib mesylate inhibits phosphorylation of EGFR, AKT and ERK, leading to apoptosis and suppression of tumor growth in mouse H1975-luc brain metastasis xenograft models. Lazertinib mesylate can be used in the study of non-small cell lung cancer [2].
loading...
    loading...
Cat. No.: HY-109061R
CAS No.: 1903008-80-9
Synonyms: YH25448 (Standard); GNS-1480 (Standard)
Lazertinib (Standard) is the analytical standard of Lazertinib (HY-109061). This product is intended for research and analytical applications. Lazertinib (YH25448) is a potent, selective, CNS-penetrant, orally available and irreversible EGFR tyrosine Kinase inhibitor, exhibiting high selectivity for activating (EGFRm) and T790M resistance mutations. Lazertinib inhibits phosphorylation of EGFR, AKT and ERK, leading to apoptosis and suppression of tumor growth in mouse H1975-luc brain metastasis xenograft models. Lazertinib can be used in the study of non-small cell lung cancer [2].
loading...
    loading...
Cat. No.: HY-112289
CAS No.: 1429179-07-6
Purity:  99.96%
Research Areas:  

Cancer

IDH889 is an orally available, brain penetrant, allosteric and mutant specific inhibitor of isocitrate dehydrogenase 1 (IDH1). IDH889 has potent selectivity for IDH1 R132* mutations, with IC50s of 0.02 μM, 0.072 μM and 1.38 μM for IDH1 R132H, IDH1 R132C and IDH1 wt, respectively. IDH889 shows potent cellular inhibition of R-2-hydroxyglutarate (2-HG) production with an IC50 of 0.014 μM .
loading...
    loading...
Cat. No.: HY-12291
CAS No.: 1315329-43-1
Purity:  99.69%
Synonyms: HMSL 10017-101-1
Target:  

Raf Apoptosis

Research Areas:  

Cancer

HG6-64-1 (HMSL 10017-101-1) is a B-raf kinase modulator.HG6-64-1 modulates B-raf kinase activity, including the V600E mutant form and the drug-resistant gatekeeper mutation T529I. HG6-64-1 is a germinal center kinase inhibitor. HG6-64-1 induces cell cycle arrest and apoptosis. HG6-64-1 can be used for the research of diffuse large B-cell lymphoma (DLBCL) [2].
loading...
    loading...
Cat. No.: HY-132604A
CAS No.: 2175009-09-1
Purity:  93.86%
Synonyms: ARO-AAT sodium
Research Areas:  

Metabolic Disease

Fazirsiran sodium is a second-generation RNAi agent. Fazirsiran sodium consistes of a cholesterol-conjugated RNAi trigger (chol-RNAi) to selectively degrade Alpha1-antitrypsin (AAT) mRNA by RNAi and a melittin-derived peptide conjugated to N-acetylgalactosamine (NAG) formulated as the excipient EX1 to promote endosomal escape of the chol-RNAi in hepatocytes . Fazirsiran sodium can be used in the study of Alpha-1 Antitrypsin Deficiency (AATD) liver disease. AATD is caused by mutations in the alpha-1 antitrypsin (SERPINA1) gene.
loading...
    loading...
Cat. No.: HY-137497
CAS No.: 300809-71-6
Purity:  99.85%
Target:  

Ras Apoptosis

Research Areas:  

Cancer

KRAS inhibitor-9, a potent KRAS inhibitor (Kd=92 μM), blocks the formation of GTP-KRAS and downstream activation of KRAS. KRAS inhibitor-9 binds to KRAS G12D, KRAS G12C and KRAS Q61H protein with a moderate binding affinity. KRAS inhibitor-9 causes G2/M cell cycle arrest and induces apoptosis. KRAS inhibitor-9 selectively inhibits the proliferation of NSCLC cells with KRAS mutation but not normal lung cells .
loading...
    loading...
Cat. No.: HY-145226
CAS No.: 2757045-94-4
Purity:  98.9%
Research Areas:  

Cancer

XY-06-007 is a mutation-selective PROTAC degrader targeting BRD4BD1L94V, with a DC50, 6 h of 10.2 nM in Flp293T cells. XY-06-007 recruits the E3 ligase CRL4CRBN to BRD4BD1L94V, triggering ubiquitination and proteasomal degradation. XY-06-007 can be combined with the dTAG strategy to achieve degrader-mediated synchronous depletion of the corresponding protein fusion in cells. XY-06-007 is applicable for cancer research .
loading...
    loading...
Cat. No.: HY-146223
Purity:  99.52%
Target:  

Ras p38 MAPK PI3K Apoptosis

Research Areas:  

Cancer

AZD4625 is an orally active, selective irreversible, covalent allosteric GTPase KRASG12C inhibitor with an IC50 of 3 nM. AZD4625 can inhibit the MAPK pathway (with decreased pCRAF, pMEK, and pERK) and the PI3K pathway (with decreased pAKT and pS6), and induce cell apoptosis. AZD4625 has no binding and inhibition of wild-type RAS or isoforms carrying non-KRASG12C mutations. AZD4625 can be used for the study of KRASG12C mutant non-small cell lung cancer [2].
loading...
    loading...
Cat. No.: HY-146408
CAS No.: 2901889-01-6
Research Areas:  

Cancer

ALK-IN-21 (Compound B10), a potent ALK inhibitor for ALKG1202R mutation, exhibits remarkable enzymatic inhibitory potency with IC50 values of 4.59 nM, 2.07 nM and 5.95 nM toward ALK WT, ALK L1196M and ALK G1202R, respectively. ALK-IN-21 efficiently inhibits the proliferation of ALK-positive Karpas299 and H2228 cells both with IC50 values of 0.07 μM. ALK-IN-21 can be used for the research of anaplastic large cell lymphoma .
loading...
    loading...
Cat. No.: HY-148273
CAS No.: 2821793-99-9
Purity:  99.42%
Synonyms: ASP-3082; KRAS G12D inhibitor 17
Target:  

PROTACs Ras ERK Akt

Research Areas:  

Cancer

Setidegrasib (ASP-3082) is a PROTAC KRAS degrader (DC50: 37 nM). Setidegrasib induces the degradation of G12D-mutation KRAS protein. Setidegrasib suppresses p-ERK, p-AKT, p-S6 levels in AsPC-1 cells. Setidegrasib exhibits anti-tumor activity in various cancer xenograft models in mice. Setidegrasib can be used in studies involving KRAS(G12D)-mutated solid tumors, such as non-small cell lung cancer [2] .
loading...
    loading...
Cat. No.: HY-15814
CAS No.: 1258391-13-7
Purity:  99.94%
Research Areas:  

Cancer

HG-7-85-01 is a type II ATP competitive inhibitor of wild-type and gatekeeper mutations forms of Bcr-Abl, PDGFRα, Kit, and Src kinases. HG-7-85-01 inhibits T315I mutant Bcr-Abl kinase, KDR and RET with IC50s of 3 nM, 20 nM and 30 nM, and is only weak or no inhibition of other kinases (IC50>2 μM). HG-7-85-01 inhibits the cell proliferation, which is mediated by the induction of apoptosis, and inhibition of cell-cycle progression .
loading...
    loading...
Cat. No.: HY-158265
Target:  

FLT3

Research Areas:  

Cancer

FLT3D835Y/F691L-IN-1 (compd 8v) is an orally active inhibitor of FLT3 3-tyrosine kinase domain D835Y/F691L secondary mutations with IC50s of 1.5 and 9.7 nM. FLT3D835Y/F691L-IN-1 can be used for acute myeloid leukemia research .
loading...
    loading...
Cat. No.: HY-160478
CAS No.: 839708-29-1
Target:  

Bcr-Abl

Research Areas:  

Cancer

GNF-6 (Compound 14) inhibits the gatekeeper threonine residue mutation of BCR-ABL-T315I with IC50s of 0.25 μM, 0.09 μM and 0.590 μM for c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants, respectively. GNF-6, an ATP competitive inhibitor, disrupts the assembly of the hydrophobic spine (a network of hydrophobic interactions), thereby locking the kinase in an inactive ‘DFG-out’ conformation .
loading...
    loading...
Cat. No.: HY-161111R
CAS No.: 3056394-59-0
Research Areas:  

Cancer

KVS0001 (Standard) is the analytical standard of KVS0001 (HY-161111). This product is intended for research and analytical applications. KVS0001 is a selective SMG1 inhibitor. KVS0001 elevates the expression of transcripts and proteins resulting from truncating mutations. KVS0001 increased the presentation of immune-targetable HLA class I-associated peptides from nonsense-mediated decay (NMD)-downregulated proteins on the surface of cancer cells. KVS0001 exerts anti-tumor properties and can be studied in research for NMD-related diseases, including cancer and inherited diseases .
loading...
    loading...
Cat. No.: HY-173500
Target:  

MMP Apoptosis EGFR STAT

Research Areas:  

Cancer

MG-3C is a potent matrix metalloproteinase 9 (MMP-9) inhibitor. MG-3C can selectively kill non-small-cell lung cancer (NSCLC) cells harboring the EGFR T790M mutation. MG-3C blocks the EGFR/STAT3 signaling pathway, inducing G2/M phase arrest, growth inhibition, and apoptosis of cancer cells. MG-3C is promising for research of lung cancer .
loading...
    loading...
Cat. No.: HY-174851
CAS No.: 2923865-76-1
Target:  

Ras

Research Areas:  

Cancer

KRAS G12C-IN-70 is a selective KRAS G12C mutant inhibitor. KRAS G12C-IN-70 blocks KRAS G12C-mediated downstream signaling pathways (e.g., RAF-MEK-ERK) and inhibits tumor cell proliferation. KRAS G12C-IN-70 is promising for research of KRAS G12C mutation-related tumors (such as non-small cell lung cancer, colorectal cancer) .
loading...
    loading...
Cat. No.: HY-181263
Target:  

SARS-CoV Virus Protease

Research Areas:  

Infection

Jun13698 is a SARS-CoV-2 main protease (M pro) inhibitor with Ki values of 65.6 nM, 510.0 nM, and 117.5 nM against the wild-type, E166V, and E166A mutants, respectively. Jun13698 forms stable complexes with wild-type and mutant M pro to mediate enzyme inhibition. Jun13698 exhibits antiviral activity against SARS-CoV-2 variants carrying the E166V/A mutation. Jun13698 is applicable to COVID-19-related research .
loading...
    loading...
Cat. No.: HY-18652A
CAS No.: 946128-90-1
Synonyms: Ro 5126766 potassium; CH5126766 potassium
Target:  

Raf MEK

Research Areas:  

Cancer

Avutometinib (CH5126766) (potassium) is a RAF/MEK clamp that potently inhibits RAF/MEK kinase activity and induces dominant negative RAF-MEK complexes preventing phosphorylation of MEK by ARAF, BRAF and CRAF. Avutometinib (potassium) shows anti-proliferative potency across tumor cell lines carrying KRAS mutations including PDAC cell lines. Avutometinib (potassium) induces tumor inhibition and increases survival in a KRAS/p53 pancreatic cancer mouse model. Avutometinib (potassium) is promising for research of low-grade-serous-ovarian-carcinoma (LGSOC), ovarian cancer and pancreatic ductal adenocarcinoma (PDAC) [2].
loading...
    loading...